Movement Alert｜10x Genomics, Inc. Falls 7.01% in Pre-Market Trading, Shares Weaken Despite Q3 Beat and Raised Revenue Outlook

Market Focus11-06

On November 6, 10x Genomics, Inc. fell 7.01% in Pre-Market Trading, trading at $58.06 per share, with turnover of $354 million.

The move followed the company’s latest quarterly report: Q3 loss was $0.15 per share, better than market expectations for a $0.25 to $0.27 loss, while revenue was $150.667 million, above estimates near $147.9 million to $148.0 million.

10x Genomics, Inc. also raised full-year revenue guidance to $625 million-$635 million from $610 million-$630 million, compared with consensus around $620.8 million. Even with the earnings beat and improved outlook, pre-market trading remained weak, indicating investors were still focused on the durability of growth and the pace of profitability improvement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment